Paying for medicinal cannabis in New Zealand

Paying for medicinal cannabis in New Zealand usually involves several separate charges, and public funding is exceptional rather than impossible. A useful estimate therefore starts with an itemised quote and the current Pharmac position, not a single advertised monthly figure.

Medicinal cannabis costs in New Zealand

The total can include an initial consultation, later clinical reviews, prescription administration, the prescribed product, pharmacy dispensing and delivery. Which charges apply depends on the prescriber, pharmacy, product, quantity and review plan. Prices and availability change, so a historic online price is not a dependable budget.

Ask the clinic for the full first-stage cost before booking. Ask whether follow-up frequency is fixed or decided clinically, whether prescription work is included, and what happens if the first prescribed product is unavailable. Then ask the dispensing pharmacy for an itemised quote that includes GST, dispensing and delivery.

Do not compare products only by bottle, pack or gram price. The prescribed formulation, strength, route and quantity may differ. A lower shelf price does not show that two products are clinically interchangeable, and a pharmacist should not be asked to substitute outside the prescription.

Pharmac funding and exceptional applications

Medicinal cannabis is not routinely funded simply because it has been prescribed or verified under the scheme. Pharmac applies its normal medicine-funding process to general applications.

For an individual, a prescriber may consider the Named Patient Pharmaceutical Assessment process when the person’s circumstances meet Pharmac’s exceptional-circumstances principles. Pharmac reports that it received nearly 50 medicinal-cannabis NPPA applications between 2021 and 2025. Nine were approved for individual patients whose circumstances were life-threatening or extremely severe and whose other treatment options had been exhausted. Most applications were declined.

Those figures support two careful conclusions. Funding is rare, and it is not accurate to say that no pathway exists. NPPA is a clinical application made by a prescriber; it is not a reimbursement form that a patient can assume will succeed.

Insurance, ACC and other assistance

Private insurance terms vary by policy and can change at renewal. Ask the insurer in writing whether the consultation, prescription service and product are treated differently, whether unapproved medicines are excluded, and what evidence is required for a claim. Do not rely on another patient’s result.

ACC or income-support assistance depends on the governing criteria and the person’s circumstances. A clinic should not promise coverage. Ask the relevant agency for a written decision or current policy and keep the prescription, invoices and clinical correspondence needed for any application.

A practical budget checklist

Before starting, record:

• the initial and follow-up consultation charges;
• expected review timing and any repeat-prescription charge;
• the pharmacy’s current product, dispensing and delivery quote;
• how long the quoted supply is expected to last under the prescription;
• whether a funding or insurance decision has actually been issued;
• what clinically appropriate alternatives the prescriber would discuss if the cost cannot be sustained.

Comparing quotes without comparing unlike treatment

Put each quote into the same set of columns: consultation work, review work, prescribed supply, dispensing, delivery and the period covered. Mark every amount that is only an estimate. A clinic’s low headline consultation charge may exclude prescription administration or follow-up, while a higher figure may bundle those services. Ask the provider to explain the difference in writing.

Do not convert cannabinoid content into a self-selected “cost per dose.” Only the prescription establishes how the product is intended to be used. The purpose of the table is to expose fees and timing, not to optimise treatment without clinical advice.

Repeat the quote when the prescription, supplier or review plan changes. Keep cost questions separate from medical decisions: a prescriber or pharmacist should assess changes to treatment, while Pharmac, an insurer or another agency decides funding under its own rules.